Question-and-Answer Session
Operator
(Operator Instructions) First, we will go to Geoff Meacham with JPMorgan.
Terry Coyne - JPMorgan
Hello. This is Terry Coyne for Geoff today. Thanks a lot for taking the question. My question is on the, I am wondering if you can expand a little more on your specific plans for the Phase 2 Pompe trial. You can give us some details about what that trial could look like?
John Crowley
No. The only guidance I will give here is to say that by the end of this quarter, so within the next month or two, we will be initiating that study and at that time we will be able to comment on the study design.
Terry Coyne - JPMorgan
Okay. Are there any plans to look at the Fabry and Gaucher programs in combination with ERT in the near term? Or is that something that you are just going to look at with the Pompe program for now?
John Crowley
Well, we have chosen to begin looking at the potential for combination therapy. There are several different ways, of course, to look at combination therapy. So we think it is most appropriate to begin looking in Pompe disease, both by the nature of that enzyme replacement therapy, Myozyme that treats Pompe today for many patients, but also the nature of the disease. So we think that is best in terms of meeting unmet patient needs, but also establishing the potential for proof-of-concept of a combination approach..
So we will begin and continue to advance that pre-clinical work, but we are also mindful of the potential in Fabry and Gaucher. We just think given the nature of that disease in the patient population that Pompe has a better place to begin looking at the combo therapy. Again, I will highlight that as combo therapy, in addition to our initially pursuing in the clinic, the mono therapy, chaperone AT2220. Based on the Ex Vivo study that we shared at the ACMG, we are very encouraged by that data and we do believe that a good majority of patients with Pompe disease will be amenable to the chaperone as a mono therapy. We simply want to make sure that we are leveraging the technology as best we can to meet as much of the unmet medical need with patients as we can.
Terry Coyne - JPMorgan
Okay, thanks a lot.
Operator
Thank you. Next we will go to Matt Osborne at Lazard Capital Markets.
- To read the full transcript on Seeking Alpha, click here »
